ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0628

Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 0888

Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2049

Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Abstract Number: 1355

Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis
Abstract Number: 2632

Genetically-engineered Ro-specific Regulatory T Cells to Treat Primary Sjögren’s Disease
Abstract Number: 1803

Genetics of eGFR Variability as a Proxy for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
Abstract Number: 2602

Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus
Abstract Number: 2533

Genome-wide Association of Rheumatoid Arthritis in the African Ancestry Identifies HLA Amino Acid Polymorphisms of Risk
Abstract Number: 1829

Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis
Abstract Number: 0997

Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus
Abstract Number: 1637

Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Abstract Number: 0549

Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Abstract Number: 2041

Global Prevalence and Clinical Outcomes of Cogan Syndrome
Abstract Number: 0772

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Abstract Number: 1746

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].